Solventum Corporation AI Stock Analysis
Want to see SOLV full AI Analyst Report?
Solventum Corporation (SOLV) AI Stock Analysis
Solventum Corporation
(NYSE:SOLV)
The score is held back primarily by weakened TTM profitability and especially poor recent free-cash-flow performance, alongside a moderate leverage profile. Offsetting factors include a constructive earnings-call update with raised EPS and margin outlook and generally neutral technicals, but the high P/E valuation limits upside confidence without clear, sustained earnings and cash-flow recovery.
Solventum Corporation Key Performance Indicators (KPIs)
Operating Income by SegmentReports profit after operating costs for each segment, showing which parts of Solventum generate the most earnings and where margins are under pressure. Comparing operating income across segments helps investors judge capital allocation, operational efficiency, and where management should prioritize improvements or investments.
Underlying segment profitability looks healthier than reported swings: Health Information Systems is the clear growth engine, MedSurg is drifting down modestly, Dental is stabilizing after SKU rationalization, and Purification & Filtration has been exited—explaining its disappearance and the large one‑time gain that produced the Corporate & Unallocated spike. Amortization pressure is easing. Management’s margin targets rely on Transform savings and HIS momentum, but ERP cutover and separation timing will keep quarter-to-quarter volatility elevated.
Solventum Corporation (SOLV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $15.33B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.07M
- Price to Earnings (P/E)
- 99.6
- Beta (1Y)
- 0.73
- Revenue Growth
- -3.09%
- EPS Growth
- -89.72%
- Country
- US
- Employees
- 20,584
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Solventum Corporation Business Overview & Revenue Model
Company Description
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patien...
How the Company Makes Money
Solventum makes money primarily by selling healthcare products and related solutions to providers and channel partners. Key revenue streams include: (1) consumable and procedure-driven medical products (e.g., medical/surgical supplies and solutions u...
Solventum Corporation Earnings Call Summary
The call was predominantly positive. Management reported solid execution through a highly complex ERP cutover, raised full-year EPS and operating-margin expectations, advanced the 3M separation beyond 90%, improved the supply agreement outlook, and highlighted broad product and growth-driver momentum. The principal challenges were the ERP-related timing reversal, reported and segment-level sales declines, tariff and inflation headwinds, remaining separation work, and anticipated margin dilution from the HIS separation. Overall, the stated achievements and outlook significantly outweighed the disclosed challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Solventum expects organic sales growth toward the high end of its 2.5% to 3% range; excluding the expected 100 basis point impact for SKU exits this year, this would represent growth closer to 4%, with foreign currency exchange rates having a favorable impact of approximately 100 basis points on reported sales growth. Full year gross margins are expected to be approximately 57%, including 120 basis points annual margin benefit from the Q2 tariff refund, while operating margin is expected toward the high end of the previously raised 22.2% to 22.7% range, compared with the initial fiscal year outlook of 21% to 21.5% before adding 120 basis points for tariff refunds; excluding the tariff refund benefit, this indicates an expected 100 basis points of expansion over prior year. Annual nonoperating expense is expected to be approximately $300 million, the tax rate is expected to be 19.5% to 20.5%, earnings per share are expected to be $7.20 to $7.30 versus the prior range of $7.10 to $7.20, and free cash flow is expected to be $200 million to $300 million, with a large majority in the fourth quarter; excluding separation and portfolio-related costs, free cash flow is tracking to approximately $1 billion for 2026. For RemainCo, the aggregate market growth rate and existing long-range plan organic sales growth target remain 4% to 5%, while the HIS separation is expected to result in approximately 400 basis points of annualized net operating margin dilution after considering the anticipated benefit of transition service offsets in the short term.
Solventum Corporation Financial Statement Overview
Summary
Underlying fundamentals are mixed and currently pressured: profitability deteriorated sharply in the TTM period (net margin fell to ~2% after strong double-digits previously) and cash generation weakened materially (free cash flow near-zero/negative recently), creating quality-of-earnings and capital flexibility concerns. The balance sheet is manageable but not conservative, with moderate-to-elevated leverage.
Income Statement
52NeutralBalance Sheet
60NeutralCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.16B | 8.32B | 8.25B | 8.20B | 8.13B | 8.17B |
| Gross Profit | 4.43B | 4.45B | 4.59B | 4.69B | 4.70B | 4.92B |
| EBITDA | 801.00M | 2.55B | 1.53B | 2.23B | 2.27B | 2.48B |
| Net Income | 156.00M | 1.56B | 479.00M | 1.35B | 1.34B | 1.46B |
Balance Sheet | ||||||
| Total Assets | 14.16B | 14.29B | 14.46B | 13.94B | 13.59B | 14.07B |
| Cash, Cash Equivalents and Short-Term Investments | 451.00M | 878.00M | 762.00M | 194.00M | 61.00M | 91.00M |
| Total Debt | 5.27B | 5.04B | 8.01B | 8.30B | 95.00M | 112.00M |
| Total Liabilities | 9.36B | 9.24B | 11.50B | 2.28B | 1.85B | 2.02B |
| Stockholders Equity | 4.80B | 5.05B | 2.96B | 11.67B | 11.74B | 12.06B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -10.00M | 805.00M | 1.63B | 1.43B | 1.93B |
| Operating Cash Flow | 310.00M | 369.00M | 1.19B | 1.92B | 1.68B | 2.20B |
| Investing Cash Flow | -989.00M | 2.80B | -380.00M | -230.00M | -253.00M | -278.00M |
| Financing Cash Flow | -516.00M | -3.06B | -240.00M | -1.55B | -1.46B | -1.96B |
Solventum Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOLV, the sentiment is Positive. The current price of 88.62 is above the 20-day moving average (MA) of 86.29, above the 50-day MA of 87.65, and above the 200-day MA of 78.72, indicating a bullish trend. The MACD of 0.58 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 72.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOLV.
Solventum Corporation Risk Analysis
Solventum Corporation disclosed 42 risk factors in its most recent earnings report. Solventum Corporation reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSolventum Corporation Peers Comparison
Overall Rating
WST78Outperform
AVTR66Neutral
BDX63Neutral
TFX57Neutral
SOLV52Neutral
BAX45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $28.74B | 46.03 | 21.08% | 0.22% | 12.60% | 32.05% | |
| 66Neutral | $10.55B | 31.38 | 5.96% | ― | 0.92% | ― | |
| 63Neutral | $57.91B | 51.69 | 3.67% | 1.85% | -7.40% | -28.89% | |
| 57Neutral | $6.16B | 18.79 | 9.74% | 0.87% | -29.30% | ― | |
| 52Neutral | $15.29B | 99.57 | 3.18% | ― | -3.09% | -89.72% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $13.67B | -19.09 | -11.62% | 0.15% | 5.33% | -164.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SOLV | Solventum Corporation | 88.62 | 13.40 | 17.81% | |
| BAX | Baxter International Inc | 26.34 | 7.68 | 41.13% | |
| BDX | Becton, Dickinson and Co | 214.52 | 66.52 | 44.95% | |
| TFX | Teleflex | 156.33 | 48.10 | 44.44% | |
| WST | West Pharmaceutical Services, Inc. | 412.86 | 146.99 | 55.28% | |
| AVTR | Avantor | 15.73 | 4.03 | 34.44% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
